Therefore, these results imply that miR-29c targets NFAT5, which is a prospective therapeutic target for PD, and controls the NLRP3 inflammasome to inhibit microglial inflammatory responses (Wang et al., 2020). The gene discussed is NLRP3; the disease is Parkinson disease.